There is one clinical trial.
To determinate feasibility, safety and outcome with convalescent plasma in patients with severe COVID-19 penumonia
Description: number of subjects surviving at 28 days from plasma infusionMeasure: 28 days survival Time: 28 days
Description: comparison of clinical efficacy according antibodies levelsMeasure: efficacy of plasma infusion according to antibodies levels in the infuse bags Time: 28 days
Description: we will search if clinical efficacy is better when the earlier the infusion is decidedMeasure: clinical efficacy of plasma infusion according to frame time from symptoms onset and hospitalization Time: 28 days
Description: WHO clinical scale is a measure of patient progression through the health-care system with 1 point asymptomatic patient and 10 patient deadMeasure: change in clinical WHO ordinal scale from 1 to 10 points Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports